Following these transactions, Schneider's direct ownership in Ionis Pharmaceuticals (NASDAQ:IONS) stands at 58,508 shares.

OpenAI is making a foray into scientific discovery with an AI built to help manufacture stem cells. When you think of AI’s contributions to science, you probably think of AlphaFold, the Google ...

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

Legend Biotech Corporation (NASDAQ:LEGN) is a clinical-stage company that develops, discovers, manufactures, and ...

With the use of deep learning and advanced algorithms, generative AI can promote acceleration in the design and development ...

The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent ...

This year lawyers will face an overwhelming array of fresh challenges as AI becomes more widely used by clients and firms ...

AI optimizes existing knowledge but doesn't expedite drug approval or reduce costs compared to traditional methods. Explore ...

Colossal BioSciences has raised $200 million in a new round of funding to bring back extinct species like the woolly mammoth.

The U.S. Commerce Department is rolling out new export controls on biotechnology equipment and related technology amid national security ...

The U.S. Commerce Department said Wednesday it is imposing new export controls on biotechnology equipment and related ...